All Stories

  1. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network a...
  2. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study
  3. Occupational Stress Among Italian Postgraduate Medical Trainees: A Pilot Study for the Validation of the SCOPE Questionnaire
  4. Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases
  5. Lessons Learnt From Running a Transition‐Age Youth Mental Health Outpatient Clinic in Italy: The PRecocity of Intervention in Adolescent Medicine (PRIMA) Experience
  6. The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults
  7. Prevalence and risk factors for depression in factitious disorder: a systematic review
  8. Tic-Related Obsessive–Compulsive and Eating Disorders in Dandy–Walker Variant: A Case Report and Systematic Reappraisal of Psychiatric Profiles
  9. Prenatal insomnia disorder may predict concurrent and postpartum psychopathology: A longitudinal study
  10. COVID-19-induced neuropsychiatric symptoms can persist long after acute infection: a 2-year prospective study of biobehavioral risk factors and psychometric outcomes
  11. Editorial: Case reports in autism
  12. Pediatric emergency department mental health assessments in the 2 years following the COVID-19 outbreak reveal higher vulnerability for eating disorder and suicide risk
  13. Risk of psychosis in autism spectrum disorder individuals exposed to psychosocial stressors: A 9‐year chart review study
  14. Lessons learnt while designing and conducting a longitudinal study from the first Italian COVID-19 pandemic wave up to 3 years
  15. Psychological factors associated with vaccination hesitancy: an observational study of patients hospitalized for COVID-19 in a later phase of the pandemic in Italy
  16. Editorial: Advances in understanding the pathogenetic mechanisms of neurodevelopmental disorders and neurodegenerative disease — The environment as a putative risk factor
  17. Biobehavioral Interactions between Endocannabinoid and Hypothalamic-pituitary-adrenal Systems in Psychosis: A Systematic Review
  18. Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
  19. COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection
  20. Editorial: Developmental trajectories in mental health between adolescence and adulthood
  21. Confirmation of increased and more severe adolescent mental health-related in-patient admissions in the COVID-19 pandemic aftermath: A 2-year follow-up study
  22. Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK
  23. Mentalization in young patients undergoing opioid agonist treatment: Implications for clinical management
  24. Changes in Revolving-Door Mental Health Hospitalizations during the COVID-19 Pandemic: A 5-Year Chart Review Study
  25. Where Do Neurodevelopmental Disorders Go? Casting the Eye Away from Childhood towards Adulthood
  26. Association between stressful life events and psychosis relapse: a 2‐year prospective study in first‐episode psychosis
  27. Using Metaphors to Understand Suffering in COVID-19 Survivors: A Two Time-Point Observational Follow-Up Study
  28. Prevalence and Risk Factors for Absconding from an Open-Door, No-Restraint Inpatient Psychiatric Unit: A Single-Center Study in Italy
  29. Uncovering Mental Health Insights: Exploring Cannabis and Psychosis Link in the UK
  30. Editorial: Methods and applications in addiction psychiatry research: 2021
  31. Development and Reliability of a Questionnaire Assessing Stress, Coping, and Empathy (SCOPE) in Occupational Settings: Preliminary Evidence from Veterinarians
  32. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  33. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence
  34. Feigning Capgras Syndrome and Developmental Prosopagnosia: a rare case of Pediatric Factitious Disorder?
  35. Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis
  36. Mental health symptoms one year after acute COVID-19 infection: prevalence and risk factors
  37. The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System
  38. Sociodemographic and clinical changes in pediatric in-patient admissions for mental health emergencies during the COVID-19 pandemic: March 2020 to June 2021
  39. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)
  40. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  41. Gender-Oriented Mental Health Prevention: A Reappraisal
  42. Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence
  43. Neurodevelopmental Disorders and Psychosocial Issues Later in Life
  44. Prevention in Mental Health
  45. Further evidence on the interplay between benzodiazepine and Z-drug abuse and emotion dysregulation
  46. Additional Evidence for Neuropsychiatric Manifestations in Mosaic Trisomy 20: A Case Report and Brief Review
  47. Meet the Editorial Board Member
  48. Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry
  49. 21.5 Repercussions of the First and Second COVID-19 Waves in the Italian Pediatric Population: An Inpatient Psychiatric Emergency Study
  50. Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases
  51. Epigenetic Mediation of AKT1 rs1130233’s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing
  52. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence
  53. Effectiveness of Equine-Assisted Activities and Therapies for Improving Adaptive Behavior and Motor Function in Autism Spectrum Disorder
  54. Postural Control in Childhood: Investigating the Neurodevelopmental Gradient Hypothesis
  55. The Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome: Preliminary Evidence from a Case Series
  56. Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior
  57. Adolescent Lifestyle Behaviors, Coping Strategies and Subjective Wellbeing during the COVID-19 Pandemic: An Online Student Survey
  58. Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol
  59. 4.4 IS ALTERED SENSORIMOTOR INTEGRATION A CORE FEATURE OF TOURETTE'S DISORDER? A CASE-CONTROL STUDY
  60. 51.18 THE COVID-19 OUTBREAK IMPACT ON WELL-BEING AMONG PEOPLE WITH AUTISM SPECTRUM DISORDER IN ITALY: AN N = 527 WEB-BASED SURVEY
  61. Investigating Gait, Movement, and Coordination in Children with Neurodevelopmental Disorders: Is There a Role for Motor Abnormalities in Atypical Neurodevelopment?
  62. Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
  63. Psychosocial and Behavioral Impact of COVID-19 in Autism Spectrum Disorder: An Online Parent Survey
  64. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
  65. Medically unexplained symptoms in the times of COVID-19 pandemic: A case-report
  66. Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis
  67. Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?
  68. Cannabis and Cognition: Connecting the Dots towards the Understanding of the Relationship
  69. Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review
  70. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study
  71. The 2019 Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: A summary of topics and trends
  72. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
  73. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
  74. Is there sufficient evidence that cannabis use is a risk factor for psychosis?
  75. Stigma as the main obstacle in health care and human rights among people with mental disorders. A rights-based ethics approach
  76. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids
  77. Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study
  78. Differential gene expression analysis in blood of first episode psychosis patients
  79. Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans
  80. O3.4. DOES CANNABIS INDUCE PSYCHOSIS BY ALTERING GLUTAMATE SIGNALING IN THE STRIATUM?
  81. Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis
  82. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
  83. The Relationship Between Dissociative Experiences and Cannabis Use: a Systematic Review
  84. Correction to: The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
  85. Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study
  86. Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort
  87. Cannabis use and the development of tolerance: a systematic review of human evidence
  88. The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
  89. Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.
  90. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure
  91. S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
  92. F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY
  93. S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE
  94. Cannabis and psychosis: what do we know and what should we do?
  95. Do Cannabis Users Develop Tolerance for the Psychoactive Effects of Delta-9-tetrahydrocannabinol? an fMRI Study
  96. Neurocognitive effects of cannabis: Lessons learned from human experimental studies
  97. Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains
  98. Hyperprolactinaemia in first episode psychosis - A longitudinal assessment
  99. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
  100. Cannabis users are less sensitive to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration
  101. A Prediction Modelling and Pattern Detection Approach for the First-Episode Psychosis Associated to Cannabis Use
  102. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study
  103. The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review
  104. Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use
  105. To treat or not to treat: puberty suppression in childhood-onset gender dysphoria
  106. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence
  107. Substance use, medication adherence and outcome one year following a first episode of psychosis
  108. Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case–control study
  109. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2year follow-up study
  110. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis
  111. Dissociative symptoms in individuals with gender dysphoria: Is the elevated prevalence real?
  112. Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria
  113. Functional Genetic Variation of the Cannabinoid Receptor 1 and Cannabis Use Interact on Prefrontal Connectivity and Related Working Memory Behavior
  114. Poster #M195 THE INTERACTION BETWEEN CNR1 GENETIC VARIATION AND CANNABIS EXPOSURE PREDICTS PREFRONTAL FUNCTIONAL CONNECTIVITY AND BEHAVIOR DURING WORKING MEMORY
  115. Attachment Styles in Transsexual Patients and Clinical and Nonclinical Control Groups: A Response
  116. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: Results from a longitudinal study
  117. Hormonal Treatment Reduces Psychobiological Distress in Gender Identity Disorder, Independently of the Attachment Style
  118. Poster #103 INTERACTION BETWEEN COMT GENOTYPE, CANNABIS USE, AND BFQ MEASURES OF SOCIABILITY
  119. Poster #35 STUDYING EPISODIC MEMORY CEREBRAL NETWORK: A NOVEL EVENT-RELATED TASK FOR FMRI
  120. COGNITIVE DEFICITS AS INTERMEDIATE PHENOTYPE IN SCHIZOPHRENIA